Literature DB >> 18612909

Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability.

Michael Brandl1, Xiaoyang Wu, Marites Holper, Lei Hong, Zhongjiang Jia, Raj Birudaraj, Micaela Reddy, Tom Alfredson, Tony Tran, Susan Larrabee, Xu Hadig, Keshab Sarma, Carla Washington, George Hill, David B Smith.   

Abstract

The nucleoside analog R1479 is a potent and highly selective inhibitor of NS5b-directed hepatitis C virus (HCV) RNA polymerase in vitro. Because of its limited permeability, lipophilic prodrugs of R1479 were screened. Selection of the prodrug involved optimization of solubility, permeability, and stability parameters. R1626 has dissociation constant, intrinsic solubility, log partition coefficient (n-octanol water), and Caco-2 permeability of 3.62, 0.19 mg/mL, 2.45, and 14.95 x 10(-6) cm/s, respectively. The hydrolysis of the prodrug is significantly faster in the Caco-2 experiments than in hydrolytic experiments, suggesting that the hydrolysis is catalyzed by enzymes in the cellular membrane. Using GastroPlus, the physical properties of R1626 successfully predict the dose dependence of the pharmacokinetics in humans previously studied. The program predicts that if the particle size of R1626 is less than 25 microm, it will be well absorbed. Prodrugs with a solubility of greater than 100 microg/mL and permeability in the Caco-2 assay greater than 3 x 10(-6) cm/s are expected to achieve a high fraction absorbed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612909     DOI: 10.1080/03639040701836636

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  8 in total

1.  Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.

Authors:  David R Nelson; Stefan Zeuzem; Pietro Andreone; Peter Ferenci; Robert Herring; Donald M Jensen; Patrick Marcellin; Paul J Pockros; Maribel Rodríguez-Torres; Lorenzo Rossaro; Vinod K Rustgi; Thomas Sepe; Mark Sulkowski; Isaac R Thomason; Eric M Yoshida; Anna Chan; George Hill
Journal:  Ann Hepatol       Date:  2012 Jan-Feb       Impact factor: 2.400

Review 2.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

3.  Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.

Authors:  Viera Lukacova; Walter S Woltosz; Michael B Bolger
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

Review 4.  Understanding the effect of API properties on bioavailability through absorption modeling.

Authors:  Filippos Kesisoglou; Yunhui Wu
Journal:  AAPS J       Date:  2008-11-06       Impact factor: 4.009

5.  Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir.

Authors:  Yen-Liang Chen; Nahdiyah Abdul Ghafar; Ratna Karuna; Yilong Fu; Siew Pheng Lim; Wouter Schul; Feng Gu; Maxime Herve; Fumiaki Yokohama; Gang Wang; Daniela Cerny; Katja Fink; Francesca Blasco; Pei-Yong Shi
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 6.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

Review 7.  Broad-Spectrum Antiviral Strategies and Nucleoside Analogues.

Authors:  Robert J Geraghty; Matthew T Aliota; Laurent F Bonnac
Journal:  Viruses       Date:  2021-04-13       Impact factor: 5.048

Review 8.  Chutes and ladders in hepatitis C nucleoside drug development.

Authors:  Steven J Coats; Ethel C Garnier-Amblard; Franck Amblard; Maryam Ehteshami; Sheida Amiralaei; Hongwang Zhang; Longhu Zhou; Sebastien R L Boucle; Xiao Lu; Lavanya Bondada; Jadd R Shelton; Hao Li; Peng Liu; Chengwei Li; Jong Hyun Cho; Satish N Chavre; Shaoman Zhou; Judy Mathew; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2013-11-23       Impact factor: 5.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.